Sun Genomics, Inc.

San Diego, California

Classification

Private

About

About

Sun Genomics, Inc., operating under the brand name Flore, is a biotechnology company specializing in personalized probiotics and gut health solutions. With a mission to improve overall health and well-being through a focus on the gut microbiome, Sun Genomics develops innovative probiotic formulations tailored to individual needs. Through advanced DNA sequencing technology and data analytics, the company provides personalized recommendations to optimize gut health and enhance the overall quality of life for its customers. Product/Service Line Breakdown: Gut Microbiome Testing: Sun Genomics offers gut microbiome testing kits that allow customers to collect stool samples at home. These samples are then sent to the company's state-of-the-art laboratory for analysis using advanced DNA sequencing techniques. The testing provides valuable insights into the composition and diversity of the gut microbiome, identifying specific bacterial strains and their abundance. Personalized Probiotics: Based on the results of the gut microbiome analysis, Sun Genomics formulates personalized probiotics specifically tailored to an individual's unique gut microbiome composition. The company combines the insights from DNA sequencing with a proprietary algorithm to identify the most beneficial probiotic strains for each customer. These personalized probiotics are designed to restore and maintain a healthy gut microbiome balance. Probiotic Subscription Service: Sun Genomics operates a subscription-based service where customers receive regular shipments of their personalized probiotics. The subscription model ensures a consistent supply of probiotics to support long-term gut health and wellness. The company may offer different subscription plans based on individual needs and preferences, allowing customers to easily manage their probiotic regimen. Gut Health Consultations: Sun Genomics provides personalized consultations with healthcare professionals specializing in gut health and the gut microbiome. These consultations help customers understand their gut microbiome test results, interpret the data, and receive expert guidance on optimizing gut health. The consultations may also involve dietary and lifestyle recommendations to complement the use of personalized probiotics. Research and Development: Sun Genomics invests in ongoing research and development activities to advance the understanding of the gut microbiome and develop new probiotic formulations. The company collaborates with academic institutions and scientific experts to explore the potential of gut health in various health conditions and disease prevention. The insights gained from research contribute to the continual improvement and innovation of Sun Genomics' products and services. Education and Resources: Sun Genomics is committed to educating the public about the importance of gut health and the role of the gut microbiome in overall well-being. The company provides educational resources, blog articles, and webinars to empower individuals with knowledge about gut health, probiotics, and related topics. These resources aim to support customers in making informed decisions about their gut health journey. Corporate Wellness Programs: Sun Genomics offers corporate wellness programs to businesses interested in promoting employee well-being and productivity through improved gut health. These programs may include gut microbiome testing for employees, personalized probiotic recommendations, educational workshops, and ongoing support for optimizing gut health in the workplace.

Financials

Revenue & Profit

Revenue

Valuation

Valuation

Ratios

Revenue / EBITDA
$123 MM
Valuation / Revenue
$123 MM
Valuation / Employees
$123 MM
EBITDA / Revenue
$123 MM
1-Year CAGR (Revenue)
03
3-Year CAGR (Revenue)
11
1-Year CAGR (Employees)
19
3-Year CAGR (Employees)
96

People

Employee Figures

Employees

Key Executives

NameTitleSocialsEmailPhone
John DoeEmployee
--
Jane DoeEmployee
John DoeEmployee
John DoeEmployee

401K

Total Active Participants
1234
No. Participants with Account Balances
56789
Total Liabilities Start of Year
1234
Total Assets Start of Year
56789

Deals

M&A2024-03-15Completed

Seller

Founders Group

Investor Sponsors

NorthBridge PE

Deal Amount

$120M

Target Company Valuation

$1.20 MM

Techniques

Acquisition of Assets, Taken Private

Stake Tags

100%

Is PE deal

Yes

Is deal PE backed

Yes

Total Acquired

100%

Secondary Transaction2023-09-01Canceled

Target

BrightHealth Technologies

Seller

Early Investors Consortium

Investor Sponsors

--

Deal Amount

Undisclosed

Target Company Valuation

NaN

Techniques

Secondary Sale, Management Buy-out (MBO)

Stake Tags

Majority

Is PE deal

No

Is deal PE backed

Yes

Total Acquired

65%

Funding

Keywords

Keywords

Classified

Private